menu
    • menu

    Company profile for Shanghai Henlius Biotech

    NEW Drugs in Dev: 53
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a global biopharmaceutical company focusing on oncology and auto-immune diseases with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide. Founded in 2010 and headquartered in Shanghai, we have built three global R&D facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost-efficient R&D processes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Shanghai Henlius BiotechChina Flag
    Country
    Country
    China
    Address
    Address
    9/F, Innov Tower, Zone A, No. 1801 Hongmei Road, Xuhui District, Shanghai
    Telephone
    Telephone
    021-33395800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.henlius.com/en/Index.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Henlius Advances Global Development of PD-L1 ADC at ASCO
    Henlius Advances Global Development of PD-L1 ADC at ASCO

    01 Jun 2026

    // PRESS RELEASE

    https://www.henlius.com/en/NewsDetails-5956-26.html

    PRESS RELEASE
    01 Jun 2026
    Share Share
    Henlius' Pertuzumab Approved in China; First China-US-EU Combo
    Henlius' Pertuzumab Approved in China; First China-US-EU Combo

    29 May 2026

    // PRESS RELEASE

    https://www.henlius.com/en/NewsDetails-5955-26.html

    PRESS RELEASE
    29 May 2026
    Share Share
    Henlius Doses First China Patient in PD-L1 HLX43 Phase 2/3 Trial
    Henlius Doses First China Patient in PD-L1 HLX43 Phase 2/3 Trial

    28 May 2026

    // PRESS RELEASE

    https://www.henlius.com/en/NewsDetails-5954-26.html

    PRESS RELEASE
    28 May 2026
    Share Share
    Henlius Doses First Patient in China Phase 1 Trial of HLX15-SC
    Henlius Doses First Patient in China Phase 1 Trial of HLX15-SC

    26 May 2026

    // PRESS RELEASE

    https://www.henlius.com/en/NewsDetails-5949-26.html

    PRESS RELEASE
    26 May 2026
    Share Share
    Henlius to Disclose Key PFS Data of PD-L1 ADC HLX43 for 1st Time
    Henlius to Disclose Key PFS Data of PD-L1 ADC HLX43 for 1st Time

    25 May 2026

    // PRESS RELEASE

    https://www.henlius.com/en/NewsDetails-5947-26.html

    PRESS RELEASE
    25 May 2026
    Share Share
    Henlius' Serplulimab Gets Positive CHMP Opinion for sqNSCLC
    Henlius' Serplulimab Gets Positive CHMP Opinion for sqNSCLC

    24 May 2026

    // PRESS RELEASE

    https://www.henlius.com/en/NewsDetails-5939-26.html

    PRESS RELEASE
    24 May 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Shanghai Henlius Biotech and get a quotation

    Shanghai Henlius Biotech is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find MANUFACTURING AND CONTROL OF RHUPH20 bulk with DMF offered by Shanghai Henlius Biotech

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search